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Stimulation of superoxide 
production increases fungicidal 
action of miconazole against 
Candida albicans biofilms
Kaat De Cremer1,2, Katrijn De Brucker1, Ines Staes1, Annelies Peeters1, Freija Van den 
Driessche3, Tom Coenye3, Bruno P. A. Cammue1,2 & Karin Thevissen1
We performed a whole-transcriptome analysis of miconazole-treated Candida albicans biofilms, 
using RNA-sequencing. Our aim was to identify molecular pathways employed by biofilm cells of this 
pathogen to resist action of the commonly used antifungal miconazole. As expected, genes involved 
in sterol biosynthesis and genes encoding drug efflux pumps were highly induced in biofilm cells 
upon miconazole treatment. Other processes were affected as well, including the electron transport 
chain (ETC), of which eight components were transcriptionally downregulated. Within a diverse 
set of 17 inhibitors/inducers of the transcriptionally affected pathways, the ETC inhibitors acted 
most synergistically with miconazole against C. albicans biofilm cells. Synergy was not observed 
for planktonically growing C. albicans cultures or when biofilms were treated in oxygen-deprived 
conditions, pointing to a biofilm-specific oxygen-dependent tolerance mechanism. In line, a correlation 
between miconazole’s fungicidal action against C. albicans biofilm cells and the levels of superoxide 
radicals was observed, and confirmed both genetically and pharmacologically using a triple superoxide 
dismutase mutant and a superoxide dismutase inhibitor N-N′-diethyldithiocarbamate, respectively. 
Consequently, ETC inhibitors that result in mitochondrial dysfunction and affect production of reactive 
oxygen species can increase miconazole’s fungicidal activity against C. albicans biofilm cells.
Candida albicans, the major fungal pathogen of humans, has the capacity to form biofilms on biotic surfaces 
throughout the human gastro-intestinal tract and genital area. While this fungus can cause life-threatening inva-
sive infections in immunocompromised patients, many more individuals are confronted with superficial mucosal 
infections. Though the latter type of infection is often rather harmless and easy to treat, the incidence of recurrent 
oral and vulvovaginal candidiasis is significant. About 70% of all premenopausal woman develop vulvovaginal 
candidiasis at some point in their lives1 and repeated attacks affect at least 75 million women annually2. Currently 
the preferred treatment of such infections remains a topical azole treatment3.
Azoles, including imidazoles (e.g. miconazole) and triazoles (e.g. fluconazole), interfere with the biosynthesis 
of ergosterol by inhibiting the enzyme lanosterol 14-alpha-demethylase. Since ergosterol is a major constituent of 
the fungal membrane, its depletion results in growth inhibition4. This inhibitory effect is augmented by the accu-
mulation of toxic ergosterol precursors5. Some azoles such as miconazole, induce accumulation of reactive oxygen 
species (ROS) in planktonic and biofilm fungal cells6–12. In contrast to other azole-type antifungals, a fungicidal 
effect of ROS-inducing miconazole against biofilms of several C. albicans strains was reported when used in high 
(millimolar) concentrations10,11, but the causal relationship between induction of ROS and fungicidal activity 
remains under debate13,14. Interestingly, targeting C. albicans’ oxidative defence system to sustain high ROS levels 
reportedly enhances the fungicidal activity of ROS-inducing antifungals6,11,13,15,16.
Given the high tolerance of C. albicans biofilm cells to miconazole14, we aimed at obtaining more insight in the 
molecular pathways that are employed by the biofilm cells to resist miconazole treatment. Compounds known 
to affect these particular processes and pathways might result in an increased and potentially fungicidal action 
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(at lower concentrations) of miconazole against C. albicans biofilm cells, which is highly desirable in the context 
of developing novel biofilm eradication strategies.
Gene expression profiling of drug-treated cell populations is a useful strategy to obtain new insights in the 
drug’s mode of action, as well as in tolerance mechanisms against the drug17–19. To our knowledge, there are 
currently no transcriptome datasets available of miconazole-treated C. albicans biofilm nor planktonically grown 
cells. However, a single report documents the transcriptional response of C. albicans biofilm cells against another 
azole, namely fluconazole20. In the latter study, the transcriptome changes in biofilm cells were studied after 
30–120 min of fluconazole exposure. However, using this setup, the authors found only 5 differentially expressed 
genes.
In the present study, a whole-genome transcriptional analysis of miconazole-treated C. albicans biofilm cells 
was performed at 4 h and 24 h post miconazole treatment. By targeting particular miconazole-affected pathways 
identified via this transcriptomic approach we successfully identified compounds that increase the sensitivity of 
the C. albicans biofilm cells to miconazole. However, this potentiating effect was not observed in planktonic C. 
albicans cultures. Interestingly, the increased killing by synergistic combinations of miconazole and such specific 
inhibitors correlated with an increased production of superoxide radicals in the biofilm cells under aerobiosis. 
In line, the observed synergy between miconazole and the inhibitors under aerobic conditions was no longer 
apparent when biofilms were treated in anaerobic conditions, pointing to biofilm-specific miconazole tolerance 
pathways aimed at reducing superoxide production in the presence of oxygen. The latter was confirmed geneti-
cally using a triple superoxide dismutase mutant and pharmacologically using a superoxide dismutase inhibitor 
N-N′ -diethyldithiocarbamate.
Results
Transcriptional analysis of miconazole-treated C. albicans biofilms. In order to find pathways 
and processes involved in generating tolerance of C. albicans biofilm cells against miconazole, we performed a 
genome-wide transcriptome analysis of C. albicans SC5314 biofilms treated with miconazole. First, twenty-four 
hour old C. albicans biofilms were treated for an additional 24 h with a concentration series of miconazole to 
determine the minimal concentration needed to reduce the metabolic activity to 50% (i.e. the minimal biofilm 
eradicating concentration or BEC50 = 75 μ M measured with the metabolic activity dye Cell-Titre Blue (CTB); 
data not shown). Next, 24 h old C. albicans biofilms treated for 4 h and 24 h with 75 μ M miconazole or mock-treat-
ment (0.5% DMSO) were collected from three independent experiments and RNA was isolated. RNA-sequencing 
(RNA-seq) generated an average of 8,325,004 reads per sample of which on average 6,459,852 aligned uniquely 
with annotated coding sequences of the C. albicans SC5314 genome (Supplementary Table S1). Using EdgeR, we 
compared the gene expression level of each gene in the miconazole-treated samples with control samples for both 
time points, identifying a total of 323 and 828 differentially expressed (DE) genes at 4 h and 24 h after miconazole 
treatment, respectively (Supplementary Data S1). The number of overlapping up- and down-regulated genes is 
summarized in Fig. 1.
To examine the transcriptional response of C. albicans biofilms upon miconazole treatment, we first looked 
into the top-induced and –repressed genes (colour-indicated in Supplementary Data S1), after which we per-
formed gene ontology (GO) analysis of the whole dataset.
Among the top-50 induced genes, expected miconazole-tolerance targets were found at both time points. 
More specifically, many ergosterol biosynthesis genes (ERG6, ERG251, ERG3 and ERG2 at both time points), 
genes encoding drug efflux pumps (CDR2 and orf19.4531 at both time points and MDR1 only at 24 h post treat-
ment) and a superoxide dismutase which protects against oxidative stress (SOD5 only at 24 h post treatment) 
were highly induced by miconazole. These data corroborate with previous studies demonstrating a role for these 
genes in azole resistance, also in C. albicans biofilms11,21–24. Interestingly, genes coding for degradative enzymes 
such as secreted aspartic-type proteinases (SAP3, SAP4 and SAP6 at both time points) and lipases (LIP5 at both 
time points and LIP8 only at 24 h after treatment) were also highly induced. Induction of expression of SAP genes 
Figure 1. Number of significant (overlapping) differentially expressed genes 4 h and 24 h after miconazole 
treatment. Using EdgeR, a negative binomial distribution of the count reads was the basis to select differentially 
expressed genes between miconazole treated and untreated samples at both time points, with a limited false 
discovery rate (FDR adjusted p-value < 0.01).
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(SAP2 and SAP9) was observed previously in C. albicans after treatment with fluconazole and this was confirmed 
at protein level, also for miconazole25. Interestingly, the expression of multiple SAP and LIP genes is upregulated 
in untreated C. albicans biofilms compared to a planktonic culture as well26. However, no evidence for a role of the 
Saps or lipases in the tolerance mechanisms against azoles or in their mode of action currently exists. Potentially, 
this induction is only relevant in vivo to invade surrounding tissue and escape the drug treatment. Also the 
expression of many genes encoding cell wall proteins (PGA31, PGA37, orf19.675, PGA23 and SIM1 at both time 
points, RHD3 and SCW11 only at 4 h post treatment and PGA22 only at 24 h post treatment) and of a putative 
nicotinic acid transporter (TNA1 at both time points) was highly induced, while these genes have not been linked 
to miconazole’s mode of action or tolerance pathways in biofilm cells. The biofilm transcriptional response to 
miconazole treatment suggested a broad disturbance of energy metabolism, illustrated by the high induction 
of genes encoding the key glyoxylate enzyme isocitrate lyase (ICL at both time points) and several fermentation 
enzymes ADH3 (only at 4 h post treatment) and ADH4 and ADH5 (only at 24 h post treatment). Fermentation 
was recently reported to be specifically induced during C. albicans biofilm formation compared to stationary 
phase planktonic cells, possibly because of the hypoxic environment within C. albicans biofilms27,28, which might 
be stimulated when treated with ROS-inducing compounds such as miconazole. Moreover, multiple amino acid 
metabolism genes (LEU1 and MET3 at both time points, GDH3 only at 4 h post treatment and CAR2 only at 
24 h post treatment) were highly induced. In addition, a gene encoding a putative secreted acid sphingomyelin 
phosphodiesterase (orf19.4707, induced at both time points), IPT1 (induced at 4 h post treatment only), which 
catalyses the synthesis of the most abundant sphingolipid mannose-(inositol-P)2-ceramide and LCB4 (induced at 
24 h post treatment only), encoding a sphingosine kinase, were induced (Supplementary Data S1). Interestingly, 
both C. albicans and Saccharomyces cerevisiae mutants affected in sphingolipid biosynthesis, including ipt1 and 
lcb4, portray altered miconazole-susceptibility, confirming a possible role for these sphingolipids in miconazole’s 
mode of action29,30.
Whereas a large overlap was observed between the top genes induced at 4 h and 24 h after miconazole 
treatment, we found more differences between both time points when comparing the top-repressed genes 
(Supplementary Data S1). The most notable down-regulated genes were those involved in arginine biosynthesis 
(CPA1, CPA2, ARG1, ARG3, ARG4 and ARG8 and to lesser extent also ARG11 and ARG5,6) which was only 
observed at 24 h post miconazole treatment. Also two putative gamma-aminobutyric acid transaminase encoding 
genes (UGA1 and UGA11) are only repressed at 24 h post miconazole treatment. For both processes, no obvi-
ous link with miconazole actions has been described. At 4 h post miconazole treatment, the repression of genes 
involved in iron homeostasis (FRE7 and FRE30) was evident, and this downregulation was still ongoing at 24 h 
post treatment (although at lower reduction levels). Interestingly, the catalase-encoding gene CAT1, conferring 
resistance to oxidative stress, was also repressed at both time points (most pronounced at 4 h post treatment), 
which is in line with our previous hypothesis linking the miconazole-induced ROS production to miconazole’s 
direct inhibition of ROS-degrading enzymes such as catalase7. Other top-repressed genes, which are significantly 
differentially expressed at both time points, include ARO10 (aromatic decarboxylase), FDH1 (formate dehydro-
genase), GLT1 (a putative glutamate synthase), MSH6 (potentially involved in mismatch repair via interacting 
selectively and non-covalently with double-stranded DNA containing a single base insertion or deletion), NGT1 
(N-acetylglucosamine-specific transporter) and the transcriptional regulator of cell cycle gene expression, NRM1 
(Supplementary Data S1).
Gene ontology analysis. In parallel to a gene-specific expression analysis of the top-induced and -repressed 
genes, we also focused on the entire gene expression profile by performing a gene ontology (GO) enrichment 
analysis. This enables us to identify groups of differentially expressed genes representing different biological pro-
cesses, molecular functions or cellular components (Supplementary Data S2). In Fig. 2 we depicted the most 
unique GO categories overrepresented in the corresponding gene lists.
At 4 h post miconazole treatment, genes coding for sterol biosynthesis and related GO categories were signif-
icantly overrepresented among the induced genes, as well as those coding for ion transport and genes encoding 
proteins located in the extracellular region, cell surface and plasma membrane (Fig. 2 and Supplementary Data S2). 
Gene groups significantly over-represented in the down-regulated gene lists at 4 h post miconazole treatment 
included those correlated with calcium:proton antiporter activity, single base insertion or deletion binding and 
cellular bud (Fig. 2 and Supplementary Data S2).
At 24 h post miconazole treatment, sterol biosynthesis and related GO categories were again among the most 
pronounced induced GO categories. The GO category ‘other small molecule biosynthetic processes’ was also 
significantly induced and the concomitant induction of the organo-nitrogen compound metabolic process sug-
gests these small molecules are mainly related to metabolism of amino acids, although pyridoxine biosynthesis 
genes were also represented in this category (PDX3, SNO1 and RKI1). Additionally, one-carbon metabolic pro-
cess (mainly genes involved in tetrahydrofolate interconversion) was significantly induced at 24 h post micona-
zole treatment. Regarding cellular components, many genes encoding for proteins located on the cell surface 
and plasma membrane were induced. Gene groups significantly over-represented in the down-regulated gene 
lists at 24 h post miconazole treatment included the glutamine family amino acid biosynthetic process (linked 
to synthesis of glutamate, glutamine, arginine and proline of which mainly arginine biosynthetic genes were 
down-regulated at 24 h post miconazole treatment), oxidation-reduction process and cellular respiration (includ-
ing eight components of the respiratory electron transport chain (ETC), namely COX6, COX9, CYT1, RIP1, 
QCR2, QCR7, QCR9 and orf19.913.2). Also the GO categories related to molecular function and cellular compo-
nent illustrate the repression of the ETC (Fig. 2 and Supplementary Data S2). Finally, the GO analysis revealed 
down-regulation of genes encoding multiple mitochondrial ribosomal constituents (MRP17, MRP20, MRPS9, 
MRPL10, MPRL36, MRPL37, orf19.4751, orf19.1662, orf19.3348, orf19.3022, orf19.585, orf19.2639, orf19.688: 
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orf19.549 and orf19.6136). This repression could additionally lead to reduced respiration (including reduced ETC 
activity), the core function of proteins synthesized by mitochondrial ribosomes.
The apparent transcriptional downregulation of components of the ETC by miconazole in C. albicans biofilm cells 
hinted us to compare the current RNA-seq dataset (24 h post miconazole treatment) with a transcriptome study of C. 
albicans cells growing in hypoxic conditions31. Forty-two out of 245 hypoxia-induced genes (17%) were also induced 
in miconazole-treated C. albicans biofilms. Among these genes were the transcriptional regulator UPC2, many ergos-
terol biosynthesis genes (ERG1, ERG3, ERG5, ERG11 and ERG251), the alcohol dehydrogenase encoding gene ADH5 
and the transcriptional regulator gene RAS2. On the other hand, 22 out of 164 hypoxia-repressed genes (13%) were 
also significantly down-regulated in miconazole-treated C. albicans biofilms. Many of the common down-regulated 
genes were involved in oxidative respiration (TYE7, QCR2, CYT1, QCR7, RIP1, orf19.4016, NDH51), arginine bio-
synthesis (CPA1, CPA2, ARG11 and ARG5,6) and Fe homeostasis (FRE7, FTR2 and orf19.7077). Interestingly, the 
similarity between the hypoxic condition and azole treatment was previously described for planktonic C. albicans 
cultures upon ketoconazole addition (which is also an imidazole, like miconazole)31.
Validation of the RNA-seq data was performed for both time points by qRT-PCR on a selection of 16 genes 
representing different biological processes that were transcriptionally affected, as described above (Supplementary 
Fig. S1). The resulting logFC values obtained by qRT-PCR were completely in line with the normalized logFC val-
ues from the RNA-seq data calculated with EdgeR (Pearson correlation coefficient = 0.97), thereby confirming the 
observed gene expression patterns in the RNA-seq data as basis for subsequent analysis (Supplementary Fig. S1).
Miconazole combination testing reveals biofilm-specific synergies. Processes and pathways affected 
by miconazole in C. albicans biofilms, as determined by the transcriptome analysis, can lead to the identification 
of compounds that affect the sensitivity to miconazole. Inhibitors or inducers of such pathways may act synergis-
tically or antagonistically in combination with miconazole against C. albicans biofilms, depending on the involve-
ment of the pathway in miconazole’s mode of action or biofilm tolerance against this compound. To this end, 17 
known inhibitors and inducers of miconazole-affected pathways or compounds that complement the repression 
of a certain pathway were selected. Their potential synergistic or antagonistic activity with miconazole against 24 h 
old C. albicans biofilms was assessed via checkerboard analysis and calculation of the fractional inhibitory con-
centration index (FICI) based on metabolic activity determination using CTB. Table 1 categorizes their action as 
synergistic or indifferent in combination with miconazole against C. albicans biofilms. Because of the large amount 
of identified differentially expressed genes and pathways, we were unable to tackle all of them by an appropriate 
inhibitor or inducer. Consequently, we focused on well-known and easily available compounds (Table 1).
Figure 2. Distribution of major significantly overrepresented GO categories within the significantly up- or 
down-regulated gene lists at 4 h and 24 h post miconazole treatment, respectively. The percentages represent 
the relative amount of differentially expressed genes annotated to the respective GO category within the list of 
selected differentially expressed genes. Note that the sum of all represented GO categories in each pie chart is 
not equal to 100% since some genes belong to multiple GO categories and many of the differentially expressed 
genes are unannotated or annotated to GO categories that were not significantly overrepresented. Significant 
overrepresented GO categories were determined using the GO Term Finder at the Candida Genome Database 
(CGD) website (FDR adjusted p-value < 0.05).
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Five inhibitors resulting in synergistic activity with miconazole (simvastatin, pyrithione zinc, antimycin A, 
CCCP and sodium azide) were selected for further analysis. A more detailed representation of the remaining met-
abolic activity in C. albicans biofilms after checkerboard analysis of the combined treatment of these inhibitors 
with miconazole is shown in Fig. 3. All five selected inhibitors were able to reduce the minimum miconazole con-
centration necessary to result in 50% residual metabolic activity of biofilm cells (BEC50) at least 4.4-fold (Table 2). 
The most pronounced synergistic effect with miconazole was obtained with antimycin A (FICI = 0.10). Applied at 
a concentration of 3.125 μ M, antimycin A was able to reduce the BEC50 of miconazole almost 11-fold (Table 2). 
Note that control curves of miconazole (Fig. 3) and corresponding BEC50 values (Table 2) may vary among the 
different experiments. Therefore, FICI calculations for the five selected inhibitors were based on BEC50 values as 
determined within the experiments involving the compound that is being analysed.
Of importance, one should carefully evaluate the data that measures biofilm metabolic activity (such as the 
CTB metabolic activity dye used in this study) in the presence of inhibitors of the ETC. Treatment of biofilms with 
ETC inhibitors will result in reduction of signal in such assays and control treatments should always be taken into 
account (miconazole + ETC inhibitor versus ETC inhibitor alone) as done in our FICI calculation. Moreover, we 
also investigated whether the five selected inhibitors are effective in increasing the fungicidal activity of micona-
zole against C. albicans biofilm cells by counting colony forming units (cfu) (Fig. 4). The applied inhibitor con-
centrations were selected to have no significant antibiofilm activity on their own, based on the checkerboard 
analysis (Fig. 3).
Untreated biofilms contained almost 104  cfus/biofilm and the miconazole-only treatment (125 μ M) did not 
significantly affect this number (< 0.5 log units). Significant reductions in cfus compared to the control treatment 
(no miconazole and no additional inhibitor) could only be observed for the combined action of 125 μ M micona-
zole with 500 μ M simvastatin (97%), 25 μ M antimycin A (99%), 15.6 μ M CCCP (87%) or 1.25 mM sodium azide 
(95%). The largest potentiating effect was observed for antimycin A, which was able to increase the miconazole 
fungicidal capacity by 26-fold (corresponding with a reduction of almost 2 log units compared to no treatment). 
The combination of 125 μ M miconazole and 20 μ M pyrithione zinc did not result in additional reduction of cfus 
in comparison with single miconazole treatment (Fig. 4). Hence, only the synergistic activity of miconazole and 
simvastatin or ETC inhibitors on the metabolic activity of C. albicans biofilm cells translate to induced killing of 
these cells.
To investigate whether the synergistic activity of the five selected inhibitors with miconazole is biofilm-specific, 
we also assessed the activity of the above-described synergistic combinations in checkerboard assays on plank-
tonically growing C. albicans cultures (Supplementary Fig. S2). While no additional activity of miconazole in 
combination with four of the inhibitors (simvastatin, pyrithione zinc, antimycin A and sodium azide) in these 
Process or protein
Effect in miconazole 
RNAseq data Compound BEC50
Activity in combination 
with miconazolea
Inhibitors
Sterol biosynthetic process Induced Simvastatin 1.4 mM S
Secreted aspartic-type proteinases Induced Saquinavir mesylate > 500 μ M I
Lipases Induced Orlistat > 1 mM I
Glyoxylate cycle Induced Itaconate > 2 mM I
ETC Repressed Antimycin A 570 μ M S
CCCP 73 μ M S
Sodium azide 8.6 mM S
Sphingolipid biosynthesis Induced Myriocin > 100 μ M I
Alcohol dehydrogenase Induced Disulfiram > 500 μ M I
Branched-chain amino acid 
(including leucine) biosynthesis Induced Chlorosulfuron > 1 mM I
Fe-S bonds (as in Leu1 and 
many mitochondrial respiratory 
enzymes)
Induced Pyrithione zinc 275 μ M S
Tetrahydrofolate interconversion Induced Trimethoprim > 500 μ M I
Inducers
Nicotinic acid transporter Induced Nicotinic acid > 1 mM I
Arginine biosynthesis Repressed Arginine > 10 mM I
Leucine biosynthesis Induced Leucine > 2 mM I
Citric acid cycle Repressed Sodium dichloroacetate > 1 mM I
N-acetylglucosamine transporter Repressed N-acetyl-D-glucosamine > 1 mM I
Table 1.  Selection of inhibitors and inducers of the miconazole-affected pathways and combinatory action 
with miconazole against C. albicans biofilms determined by FICI calculation. aS = Synergy (FICI < 0.5), 
I = Indifference (0.5 < FICI < 4), FICI = [CA/BEC50A] + [CB/BEC50B], in which BEC50A and BEC50B are 
the BEC50 values (biofilm eradication concentration resulting in 50% remaining biofilm metabolic activity) 
of compound A and B alone, while CA and CB are the concentrations of the drugs A and B at iso-effective 
combinations, respectively. Note that CB values were derived from the whole dose-response curves, whereas CA 
values represent the actual concentration of compound A in the checkerboard experiments.
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planktonic conditions could be observed, an antagonistic effect of the ETC inhibitor CCCP on miconazole’s 
action could be seen, as confirmed by FICI calculation (FICI = 6.63 for 12.5 μ M CCCP), which is in contrast with 
the effect on C. albicans biofilms. Indeed, 12.5 μ M CCCP was able to increase the MIC50 (i.e. the minimal inhib-
itory concentration reducing planktonic cell growth with 50%) of miconazole by nearly 6-fold (Supplementary 
Fig. S2). It appears that the selected inhibitors act synergistically with miconazole against biofilm-specific toler-
ance mechanisms.
Boosting up miconazole’s ROS production in C. albicans biofilms by synergistic compounds 
results in increased fungicidal activity. The fungicidal activity of antifungal compounds has often been 
associated with the production of ROS14. Therefore, we assessed whether the observed synergistic effect between 
miconazole and the five selected inhibitors led to increased production of superoxide radicals, using dihydro-
ethidium staining. As the conversion of this dye depends on the number of live cells in the biofilm, results were 
normalized to the number of cfu/biofilm (Fig. 5).
Treatment of C. albicans biofilms with miconazole (125 μ M) resulted on average in a 3-fold increase of the 
basal superoxide accumulation of untreated biofilm cells (Fig. 5). Interestingly, our data show that all combi-
nations with fungicidal capacity against C. albicans biofilms (miconazole in combination with simvastatin or 
ETC inhibitors) cause additional superoxide production compared to treatment with the single compounds. The 
highest superoxide induction was observed for miconazole in combination with 25 μ M antimycin A (28-fold 
increase compared to treatment with miconazole alone) (Fig. 5), which corresponds with the largest reduction in 
cfus caused by miconazole in combination with this compound (Fig. 4). On the other hand, combined addition 
of pyrithione zinc (20 μ M) and miconazole does not induce an increase in superoxide levels in the C. albicans 
biofilms compared to miconazole treatment alone (Fig. 5), which again is consistent with the lack of effective 
fungicidal capacity of this combination (Fig. 4). Using the above data, we find a tight correlation between the 
fold reduction in cfu versus the fold increase in superoxide levels for biofilms treated with miconazole only 
or a combination treatment, which is confirmed by the Pearson correlation coefficient (0.95; p value = 0.0144; 
Supplementary Fig. S4).
To validate these findings further, we assessed the antibiofilm capacity of miconazole, antimycin A and the 
combination of both compounds in anaerobic conditions. Note that biofilms were grown in standard aerobic con-
ditions for these tests as done for all previous experiments and that only the treatment was performed in absence 
of oxygen. In these conditions, oxygen cannot serve as electron acceptor for the ETC and no mitochondrial ROS 
are produced. Therefore, we hypothesized that addition of antimycin A has no further effect on miconazole activ-
ity. Indeed, no significant combinatory fungicidal effect of antimycin A and miconazole, compared to miconazole 
treatment alone, is present in anaerobic conditions (Supplementary Fig. S3). Surprisingly, the effect of miconazole 
alone was more pronounced in anaerobic conditions (significant reduction in cfus of 0.8 log unit) compared to 
aerobic treatment. This observation was confirmed by metabolic staining of C. albicans biofilms treated with a 
concentration series of miconazole in both aerobic and anaerobic conditions (Supplementary Fig. S3).
Superoxide production is crucial for miconazole’s fungicidal action against C. albicans bio-
films. To confirm the link between superoxide induction and miconazole’s fungicidal capacity we explored 
the role of superoxide dismutases (Sods), enzymes that rapidly convert toxic superoxide into molecular oxygen 
Figure 3. Metabolic activity of C. albicans biofilms treated with a combination of miconazole and 
simvastatin, pyrithione zinc, CCCP, antimycin A and sodium azide. The control curve of miconazole alone 
is represented by diamonds, whereas combinations of miconazole with decreasing concentrations of other 
compound are indicated by circles, squares, triangles and reverted triangles. Data are mean ± SEM of five 
(n = 5) biologically independent experiments (each consisting of three repeats), determined with the metabolic 
activity dye CTB.
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in healthy C. albicans cells32,33. Six different Sods are present in C. albicans among which four Cu,Zn-containing 
superoxide dismutases (Sod1, Sod4, Sod5, and Sod6)32 that can be inhibited using the Cu,Zn-Sod inhibitor N,N′ 
-diethyldithiocarbamate (DDC), which chelates copper34. Our transcriptomic data revealed increased expression 
of SOD5 and SOD6 (Supplementary Table S2) at 24 h after miconazole treatment, suggesting their involvement in 
protection against these oxygen radicals. Indeed, a triple mutant in which both genes (and SOD4) were deleted, 
was hypersusceptible to miconazole compared to the wild type strain (Fig. 6a). Interestingly, no difference was 
observed in miconazole susceptibility between planktonically growing wild type and ΔΔΔsod4sod5sod6 C. albi-
cans cells as evidenced by the respective MIC values (MIC50 = 0.1 μ M for both the triple sod mutant and wild 
type C. albicans; data not shown), confirming the biofilm-specific action of miconazole-induced superoxide. 
Finally, addition of the Sod inhibitor DDC (thereby mimicking the protein profile of the triple sod mutant) lead 
to increased fungicidal activity of miconazole against C. albicans biofilms, which correlated with the rise in super-
oxide production (Fig. 6b,c).
Discussion
Miconazole is one of the most commonly recommended and effective topical antifungal treatments of e.g. vul-
vovaginal candidiasis3. In 80–90% of patients who complete the therapy, treatment with such azoles results in 
relief of symptoms and full elimination of fungal burden. Unfortunately, approximately 10–20% of women will 
be victim of complicated vulvovaginal candidiasis, requiring special therapeutic needs3. Also oral thrush, man-
ifested by C. albicans, is often treated with miconazole, but recurrence is frequent, leading to consideration of 
Concentration 
compound (μM)
BEC50 
miconazole (μM)a
Fold 
changeb FICIc
Simvastatin
 500 14 5.6 0.49
 250 30 2.6 0.54
 125 38 2.1 0.57
 62.5 44 1.8 0.60
 0 78 1.0 NA
Pyrithione zinc
 20 20 4.2 0.31
 10 19 4.4 0.26
 5 24 3.5 0.30
 2.5 52 1.6 0.63
 0 84 1.0 NA
Antimycin A
 25 6.4 12.7 0.12
 12.5 7.5 10.8 0.11
 6.25 9.9 8.2 0.13
 3.125 7.4 10.9 0.10
 0 81 1.0 NA
CCCP
 62.5 7.7 13.6 0.93
 31.25 18 5.8 0.60
 15.625 27 3.9 0.47
 7.8125 62 1.7 0.70
 0 105 1.0 NA
Sodium azide
 5,000 8.8 6.8 0.73
 2,500 16 3.8 0.56
 1,250 22 2.7 0.51
 625 25 2.4 0.49
 0 64 1.0 NA
Table 2.  Synergistic activity of simvastatin, pyrithione zinc, antimycin A, CCCP and sodium azide 
with miconazole against C. albicans biofilms. The BEC50 values are the mean ± SEM of at least five (n = 5) 
independent biological replicates (each consisting of three repeats). FICI values indicating a synergistic 
interaction are printed in bold. aBEC50 = Biofilm eradication concentration resulting in 50% remaining 
biofilm metabolic activity, calculated using nonlinear regression. The BEC50 value of simvastatin, pyrithione 
zinc, antimycin A, CCCP and sodium azide is 1.6 mM, 275 μ M, 570 μ M, 73 μ M and 8.6 mM, respectively. 
bFold change = fold increase of biofilm activity of miconazole due to the combination, calculated as (BEC50 of 
miconazole alone)/(BEC50 of miconazole in combination). cFICI = Fractional inhibitory concentration index, 
NA = Not Applicable.
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Figure 4. Number of cfus per C. albicans biofilm in the presence and absence of miconazole and/or  
(a) simvastatin, (b) pyrithione zinc, (c) antimycin A, (d) CCCP and (e) sodium azide. Black bars represent 
untreated biofilms or biofilms treated with 500 μ M simvastatin, 20 μ M pyrithione zinc, 25 μ M antimycin A, 
15.6 μ M CCCP and 1,250 μ M sodium azide alone while grey bars represent biofilms additionally treated with 
125 μ M miconazole. Data presented are the mean and SEM of at least three (n ≥ 3) independent experiments 
(each consisting of three replicates), measured by cfu counting. Two-way ANOVA statistical analysis with 
Tukey’s correction for multiple comparisons was performed to assign significant differences between treatments 
(* = p < 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001).
Figure 5. Accumulation of superoxide radicals in Candida albicans biofilms in the presence and absence 
of miconazole and/or (a) simvastatin, (b) pyrithione zinc, (c) antimycin A, (d) CCCP and € sodium azide. 
Superoxide production is expressed as fluorescence per 1000 cfus assessed by cfu counting. Black bars represent 
untreated biofilms or biofilms treated with 500 μ M simvastatin, 20 μ M pyrithione zinc, 25 μ M antimycin A, 
15.6 μ M CCCP and 1250 μ M sodium azide only while grey bars represent biofilms additionally treated with 
125 μ M miconazole. Data presented are the mean and SEM of at least three (n ≥ 3) independent experiments 
(each consisting of three replicates). Two-way ANOVA statistical analysis with Tukey’s correction for multiple 
comparisons was performed to assign significant differences between all treatments (* p < 0.05, * * p < 0.01).
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other treatments35. Most pathogenesis studies suggest recurrence to be linked to host immune defects, however, 
a role for biofilm formation during both vaginal and oral C. albicans infections and the recurrence thereof is 
suggested36,37.
In this study, we analysed the transcriptome of C. albicans biofilms treated with miconazole aiming at gain-
ing further insight in miconazole’s activity against biofilm cells and in biofilm tolerance mechanisms against 
this drug. Via RNA-seq, we identified a variety of differentially expressed genes and pathways, some of which 
confirmed previously observed miconazole actions (e.g. induction of ERG genes and genes encoding drug efflux 
pumps)21–24, while others are unreported.
Members of the ERG gene family code for ergosterol biosynthesis enzymes and their induction probably 
results in reduced efficacy of miconazole, which targets the lanosterol 14-alpha-demethylase encoded by ERG11. 
Induction of several ERG genes has been reported during biofilm development38, but contradictory, it was also 
reported that biofilm cells contain less ergosterol in their cell membranes compared to free-living cells, which 
possibly reduces the efficiency of azole antifungals affecting biosynthesis of this compound22. Genes encoding 
efflux pumps have also been reported to be upregulated during biofilm formation and development, which might 
explain the early acquisition of drug resistance23. However, C. albicans mutant strains deficient in efflux pumps 
were still fluconazole-resistant during biofilm growth, indicating that the presence of efflux pumps is not suffi-
cient to account for the observed fluconazole resistance in C. albicans biofilms22,23. Interestingly, one study reports 
on a relationship between upregulation of the efflux pump gene MDR1, fluconazole resistance and uncoupled oxi-
dative phosphorylation in C. albicans39, while fluconazole hypersusceptibility has also been observed in C. albi-
cans mitochondrial ETC complex I mutants40. The latter was confirmed by the use of ETC inhibitors (including 
antimycin A), resulting in increased sensitivity to fluconazole. The authors suggest that the hampered ATP pro-
duction results in down-regulation of efflux genes and concomitant azole susceptibility40. The down-regulation 
of calcium:proton antiporter activity (represented by VCX1 and orf19.7670) is probably related to the role of 
the calcineurin pathway in resistance against azoles41, which is reported to inhibit Vcx1-dependent H+/Ca2+ 
exchange in S. cerevisiae42.
Many of the genes repressed at 24 h after miconazole treatment are involved in cellular respiration, which has not 
been previously observed in miconazole-treated C. albicans. It was previously reported that miconazole-induced 
ROS was dependent on a functional citric acid cycle and respiratory ETC in S. cerevisiae and increased respira-
tion was confirmed in planktonically growing C. albicans when treated with miconazole12, which is in contrast to 
our data on miconazole-treated C. albicans biofilms. According to the GO analysis, other important significantly 
affected biological processes unrelated to known miconazole targets are those involving organo-nitrogen com-
pound metabolism and one carbon metabolic processes (induced at 24 h after treatment), single base insertion 
or deletion binding (repressed at 4 h after treatment) and arginine amino acid biosynthesis (repressed 24 h after 
Figure 6. Involvement of superoxide dismutases in C. albicans biofilm tolerance to miconazole.  
(a) Percentage remaining biofilm cfus in wild type (CA-IF100) and triple sod mutant (ΔΔΔsod4sod5sod6) 
after treatment with 30 μ M miconazole. A two-tailed paired Students t-test was performed to assign significant 
differences between the two strains (* p < 0.05). (b) Number of cfus per C. albicans SC5314 biofilm and (c) 
concomitant accumulation of superoxide radicals in the presence and absence of miconazole and/or DDC. 
Black bars represent untreated biofilms or biofilms treated with 10 mM DDC alone while grey bars represent 
biofilms additionally treated with 125 μ M miconazole. Data presented are the mean and SEM of four (n = 4) 
independent experiments (each consisting of three replicates). Two-way ANOVA statistical analysis with 
Tukey’s correction for multiple comparisons was performed to assign significant differences between treatments 
(* * * * p < 0.0001).
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treatment). When grown under certain conditions (e.g. miconazole stress), normal nutrition might be impeded 
and therefore other carbon sources become essential for growth and metabolism of the fungus. These can include 
amino acids, fatty acids and carboxylic acids43. Together with the observed repression of the ETC, this metabolism 
shift explains for a large part the high amount of differentially expressed genes and overlap with hypoxia-induced 
gene expression changes31.
We selected 17 inhibitors or inducers of interesting pathways based on the GO analysis and the top-affected 
genes and assessed whether these compounds acted synergistically or antagonistically in combination with 
miconazole against C. albicans biofilms. The action of five inhibitors (affecting three different targets) could be 
defined as synergistic (FICI < 0.5) in combination with miconazole against C. albicans biofilms. The pathways or 
features affected by these inhibitors were ergosterol biosynthesis, Fe/S bonds and the ETC. The lack of combina-
tion effect with miconazole for several of the selected compounds was not totally unexpected. On one hand, it is 
possible that the identified pathway is not involved in miconazole’s mode of action or biofilm tolerance against 
the compound. On the other hand, the biofilm structure might prevent the compound from reaching its target in 
the C. albicans cells.
The first compound, the HMG-CoA reductase inhibitor simvastatin, is a cholesterol-lowering drug for which 
antifungal activity has been described previously44. Both statins and azoles target the ergosterol biosynthesis 
pathway in C. albicans. Statins act more upstream compared to azoles, potentially depleting the fungal cells from 
alternative sterols and sterol precursors that could be inserted in the fungal membrane upon azole treatment45. 
Interestingly, synergy between simvastatin and azoles has been described for planktonically growing yeast cul-
tures46 as is the case for other statin-azole combinations47. However, from our data a synergistic activity between 
miconazole and simvastatin was biofilm-specific as this could not be confirmed in planktonic conditions. The 
potential of statins in systemic antifungal therapy is debated, due to the low concentrations that can be reached in 
blood. Moreover, the combination of statins with azole antifungals is questionable since azoles are potent inhibi-
tors of CYP enzymes, leading to arrested metabolism of many statins in the liver44.
The second compound, pyrithione zinc, is used in the treatment of seborrheic dermatitis48. Transcriptome 
analysis of the effect of sub-lethal concentrations of pyrithione zinc on Saccharomyces cerevisiae identified the 
strong induction of genes related to iron transport, and many of the strongly downregulated genes are related 
to the biosynthesis of cytochrome (heme). More recently, it was reported that pyrithione zinc acts through an 
increase in cellular copper levels that leads to loss of activity of Fe/S cluster-containing proteins49. Such Fe/S clus-
ters are present in many ETC proteins (repressed at 24 h after miconazole treatment) and in 3-isopropylmalate 
dehydratase (encoded by LEU1, which is one of the top-induced genes at both 4 h and 24 h after miconazole 
treatment). The observed synergistic effect between pyrithione zinc and miconazole (which was only effective in 
inhibition of metabolic activity, not in effectively killing the C. albicans biofilms) could be the consequence of zinc 
pyrithione’s action on these types of enzymes. Interestingly, several synergistic combinations of pyrithione zinc 
with azoles have been described and some of these are on the market for the treatment of fungal topical infections. 
For example, combinations between ketoconazole or climbazole and pyrithione zinc have proven effective to treat 
seborrheic dermatitis, a fungal skin infection condition50.
A similar mechanism might be the basis for the synergistic fungicidal effect of miconazole in combination with 
the last three compounds (antimycin A, CCCP and sodium azide), known inhibitors of the ETC. Antimycin A 
binds to the quinone reduction site of complex III, thereby inhibiting the oxidation of ubiquinol in the ETC51. The 
inhibition of this reaction disrupts the formation of the proton gradient across the inner membrane. Moreover, 
toxic ROS are formed52. Sodium azide blocks the mitochondrial respiratory chain at complex IV and this action 
reportedly decreases cellular superoxide levels53, although augmentation of ROS levels has been reported as well 
after treatment of different cell types with inhibitors of complex IV54. In contrast, the protonophore CCCP does 
not act on one particular ETC complex, but it generally enables protons to cross lipid bilayers, thereby separating 
the flow of electrons and the pumping of H+ ions. The latter implies that the energy from electron transfer can-
not be used for ATP synthesis55. Also for CCCP treatment both induction and reduction of ROS levels has been 
reported56,57.
We further attempted to unravel the role for ROS in the fungicidal combinations of miconazole and ETC 
inhibitors antimycin A, CCCP and sodium azide, by measuring the amount of superoxide radicals present after 
treatment. In addition, we included simvastatin and pyrithione zinc in this assay. Only the combinations that were 
able to effectively kill C. albicans biofilms (miconazole in combination with simvastatin, antimycin A, CCCP or 
sodium azide, as validated by cfu counting) showed a significant increase in superoxide production compared to 
single compound treatment. In contrast, the synergistic combinatory effect of pyrithione zinc with miconazole, 
which was only observed after metabolic staining and not confirmed by cfu counting, was not associated with 
increased superoxide levels. Moreover, a significant correlation was observed between the fold reduction in cfus 
versus fold increase in superoxide levels for C. albicans biofilms treated with miconazole only or treated with 
miconazole and inhibitor.
It was previously described that miconazole induces an oxidative-damage pathway in planktonically growing 
C. albicans cultures leading to cell death as a result of the production of ROS via the citric acid cycle and respira-
tory chain12. Our data of miconazole-treated C. albicans biofilms points to an opposite effect occurring in sessile 
structures. Miconazole treatment results in down-regulation of the citric acid cycle and the respiratory chain and 
it appears that miconazole’s antibiofilm effect is enhanced by perturbing the latter. Previous biofilm transcrip-
tomic and metabolomic profiling studies have demonstrated that mitochondrial respiration is down-regulated 
in mature C. albicans biofilms compared to planktonic growth28,58,59, suggesting this might be part of a protec-
tive mechanism for C. albicans biofilms as we show for miconazole in this study. The observed down-regulation 
of cellular respiration in the miconazole-treated C. albicans biofilms in this study suggests that these cells are 
attempting to halt toxic ROS production when treated with miconazole, a feature possibly unique to biofilm cells 
(in contrast with planktonic cultures), making them more tolerant to miconazole action. A similar observation 
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was previously made in tobramycin-treated biofilms of the Gram-negative bacterium Burkholderia cenocepacia60. 
Compounds that restore the ROS-inducing capacity of miconazole appear to act synergistically with miconazole 
against C. albicans biofilms and reduce the living population within the biofilm. The ETC inhibitors probably 
succeed in this action by causing an imbalance in electron transport resulting in increased ROS production (and 
therefore increased fungicidal activity) by miconazole. Additionally, also inhibition of sterol precursor biosyn-
thesis (by simvastatin) in combination with miconazole appears to synergistically increase superoxide induction 
and fungicidal capacity. In line, when tested under anaerobic conditions, the combination of antimycin A and 
miconazole had no synergistic activity against C. albicans biofilms. The crucial role of superoxide in the antibi-
ofilm activity of miconazole was illustrated by the increased miconazole-sensitivity of the ΔΔΔsod4sod5sod6 
mutant, which is hampered in detoxification of superoxide. Moreover, combination treatment of C. albicans bio-
films with miconazole and the Sod inhibitor DDC, confirmed the mutant phenotype. Note that DDC was previ-
ously reported to also reduce the levels of persister cells within miconazole-treated C. albicans biofilms11.
In conclusion, our results show that the above described synergistic combinations (under aerobic con-
ditions) between miconazole and simvastatin, pyrithione zinc or ETC inhibitors are biofilm-specific and lead 
in case of simvastatin and ETC inhibitors to increased killing of C. albicans biofilm cells. Hence, inhibition of 
biofilm-specific miconazole-affected pathways seems a promising route for the rational design of fungicidal 
miconazole combinations against C. albicans biofilms.
Materials and Methods
Strains and chemicals. C. albicans strains SC531461, the homozygous triple deletion mutant in SOD4, 
SOD5 and SOD6 (ΔΔΔsod4sod5sod6 mutant) and the corresponding isogenic wild-type strain, CA-IF10033, 
were grown routinely on YPD (1% yeast extract, 2% peptone (International Medical Products, Belgium) and 2% 
glucose (Sigma-Aldrich, USA)) agar plates at 30 °C. RPMI 1640 medium (pH 7.0) with L-glutamine and without 
sodium bicarbonate was purchased from Sigma-Aldrich and buffered with MOPS (Sigma-Aldrich). Stock solu-
tions of miconazole (Sigma-Aldrich) were prepared in DMSO (VWR International, Belgium). Other chemical 
compounds were purchased at Sigma-Aldrich (pyrithione zinc, antimycin A, CCCP, sodium azide, chlorosulfu-
ron, myriocin, saquinvair mesylate, orlistat, itaconate, disulfiram, N-acetyl-D-glucosamine, sodium dichloroac-
etate and DDC) or TCI Europe (simvastatin and trimethoprim). Nicotinic acid, L-arginine and L-leucine were 
purchased at VWR International.
Transcriptomic experiment. An overnight culture of C. albicans, grown in YPD, was diluted to an optical 
density of 0.1 (approximately 106 cells/mL) in RPMI 1640 medium and 500 μ L thereof was added to the wells of a 
12-well polystyrene microtiter plate (Greiner Bio-One). After 1 h of adhesion at 37 °C, the medium was aspirated 
and biofilms were washed with 500 μ L phosphate buffered saline (PBS) to remove non-adherent cells, followed 
by addition of 500 μ L RPMI 1640 medium. Biofilms were allowed to grow for 24 h at 37 °C. Miconazole (75 μ M 
in RPMI 1640 medium) was then delivered to the biofilms (0.5% DMSO background). Biofilm samples were 
collected at 4 and 24 h after miconazole treatment for RNA isolation. Measurement of metabolic activity was per-
formed on biofilms grown in the same conditions after washing wit PBS. To this end, 500 μ L Cell-Titre Blue (CTB; 
Promega, USA)62 diluted 1/10 in PBS was added to each well. After 1 h of incubation in the dark at 37 °C, fluo-
rescence was measured and percentage of metabolically active biofilm cells was calculated as described before63.
RNA isolation. Before RNA isolation, biofilm material was washed with ice cold PBS, scraped of the bot-
tom of the plate and washed 3 times more with ice cold PBS. RNA was isolated using a hot-phenol protocol as 
described previously64, combined with mechanical disruption using acid-washed glass beads (Sigma-Aldrich) in 
the Precellys 24 (Bertin technologies; 2 × 45 s with 15 s break at 6,000 rpm). Control of the quality and integrity 
of the RNA was done with the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, USA) and the 
BioAnalyzer (Agilent, USA).
Library preparation, RNA-sequencing and data analysis. Library preparation for RNA sequencing 
was performed using the Illumina (USA) TruSeq kit and sequencing was performed in one lane of an Illumina 
HiSeq2000 sequencer using the HiSeq Reagent Kit (Illumina, USA) according to the manufacturer’s instructions. 
An average of 7,761,850 reads per sample (50 bp) was generated (Supplementary Table S1). Raw sequencing 
reads were deposited at the Sequence Read Archive of NCBI (accession number SRA306211). Low quality ends 
(Q < 20) were trimmed and adapters were trimmed at the end when there was at least a 10 bp overlap and 90% 
match. Reads that were shorter than 35 bp after trimming were removed. Poly-A reads (more than 90% of the 
bases equal A), ambiguous reads (containing N), low quality reads (more than 50% of the bases Q < 25) and 
artefact reads (all but 3 bases in the read equal one base type) were removed. After processing, 99.8% of the initial 
reads remained. Processed reads were mapped to the reference C. albicans genome SC5314_A21 with Tophat 
v2.0.8b65. We removed reads from the alignment that are non-primary mappings or have a mapping quality ≤ 20. 
An average of 93.8% of the processed reads were mapped to the reference genome. The number of mapped reads 
that overlap with gene features (using the C_albicansSC5314_version_A21_s02_m07_r10-features.gff annotation 
file66) were determined with HTSeq 0.5.4p367. Genes for which all samples have less than 1 count per million 
reads (absent genes) were not considered for differentially expressed gene analysis. For each of the 5,910 remain-
ing genes, we performed differential expression analysis for each time point (i.e. 4 h and 24 h after miconazole 
treatment) with the EdgeR package of Bioconductor, by fitting a negative binomial generalized linear model68. 
The resulting p values were corrected for multiple testing with Benjamini-Hochberg to control the false discov-
ery rate at 1%69. For identification of GO terms overrepresented in each of the differentially expressed gene lists, 
enrichment analysis was conducted with the Candida Genome Database GO Term Finder Tool70.
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Quantitative reverse transcription PCR. Primers for reverse transcription were designed using 
Primer-BLAST (www.ncbi.nlm.nih.gov/tools/primer-blast) (Supplementary Table S2). DNase treatment, reverse 
transcription and qRT-PCR analysis were carried out as described previously71. Two normalization genes, ACT1 
and EFB1, were used. Relative log2 induction ratios of treated samples compared with mock-treatment were 
calculated based on the Δ Δ Ct method72.
BEC50 determination assay. To determine the minimal concentration of the compound that results in 
50% remaining biofilm metabolic activity (BEC50) for the respective compounds, C. albicans SC5314 biofilms 
were grown and treated in a round bottomed microplate as described before63. Measurement of metabolic activity 
was performed using the metabolic activity dye CTB63.
Biofilm checkerboard assay. In order to determine possible synergistic interactions between compounds, 
checkerboard analysis and FICI calculations were performed as described before using the metabolic activity 
dye CTB63 and FICI (fractional inhibitory concentration index) was calculated as FICI = [CA/BEC50A] + [CB/
BEC50B], in which BEC50A and BEC50B are the BEC50 values of compound A and B alone, respectively, and CA 
and CB are the concentrations of the drugs A and B at iso-effective combinations, respectively73. Note that CB 
values were derived by linear regression from the whole dose-response curves, whereas CA values represent the 
actual concentration of compound A (i.e. simvastatin, pyrithione zinc, antimycin A, CCCP or sodium azide) in 
the checkerboard experiments, as indicated in Table 2. The interaction was defined as synergistic for a value of 
FICI ≤ 0.5, indifferent for 0.5 < FICI < 4 and antagonistic for FICI ≥ 4.074.
Planktonic assay. Synergistic action of compounds on planktonically growing C. albicans SC5314 cells was 
determined by FICI calculations as described above. MIC50 values (minimal concentration of the compound that 
causes a 50% reduction of planktonic cell growth), determined by OD measurement as described previously75 
were used instead of BEC50 values. Sensitivity to miconazole (MIC50) was similarly assessed for planktonically 
growing ΔΔΔsod4sod5sod6 mutant and the corresponding isogenic wild-type strain, CA-IF100.
Cfu determination and superoxide detection. Biofilms were grown and treated as described above. 
Alternatively, biofilms were grown as described above but the treatment was performed in anaerobic condi-
tions by placing the biofilm plates in a jar in the AnoxomatTM Mark II System (Advanced Instruments INC, 
Massachusetts, USA). After 24 h of treatment at 37 °C, biofilm cells were washed and dissolved in 100 μ L PBS by 
vigorously pipetting. Of this cell suspension, 10 μ L was diluted and plated out on YPD agar plates to determine 
the number of fungal cfu after 2 days of incubation at 30 °C. To determine the amount of superoxide formed, the 
remaining 90 μ L was stained by adding 10 μ L of a 200 μ M dihydroethidium (Life Technologies Europe) stock 
solution. This suspension was transferred to black-walled microplates (Greiner) and incubated for 20 min at 
room temperature in the dark. Finally, fluorescence was measured with a fluorescence spectrometer (Synergy 
Mx multi-mode microplate reader, BioTek, USA) at λ ex 510 nm and λ eem 595 nm and values were corrected for 
fluorescence measured in blank wells. Cfu determination was also performed for the ΔΔΔsod4sod5sod6 mutant 
and the corresponding isogenic wild-type strain, CA-IF100, after treatment with 30 μ M miconazole. Calculation 
of the Pearson correlation coefficient and analysis of significance was performed in GraphPad Prism 6.
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